Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

795
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
795
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

534
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
534
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

4.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.7K
Lipid Absorption01:24

Lipid Absorption

2.4K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.4K
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

6.2K
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Molecular Genetic Risk Factors for Severe Familial Hypercholesterolemia.

Journal of lipid and atherosclerosis·2026
Same author

Treatment Target Discovery From Vasculo-Protective Phenotypes.

Journal of lipid and atherosclerosis·2026
Same author

2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid.

Journal of lipid and atherosclerosis·2025
Same author

Escalating Lipid Therapy After Achieving LDL-C <70 mg/dL With Moderate-Intensity Statins in High-Risk Patients.

Korean circulation journal·2024
Same author

2024 KSoLA Consensus on Secondary Dyslipidemia.

Journal of lipid and atherosclerosis·2024
Same author

Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.

Yonsei medical journal·2023
Same journal

The Persistent Challenge of Cardiogenic Shock Complicating Acute Myocardial Infarction: Insights From a Korean Nationwide Registry.

Korean circulation journal·2026
Same journal

2026 Focus Update of the 2021 Korean Society of Myocardial Infarction Expert Consensus Document on Revascularization for Acute Coronary Syndromes.

Korean circulation journal·2026
Same journal

Mitral Annular and Aortic Calcification in Aortic Stenosis: Risk Marker or Bystander?

Korean circulation journal·2026
Same journal

The Quest for Longevity in Pulmonary Valve Replacement: Translating Experimental Insights Into Surgical Excellence.

Korean circulation journal·2026
Same journal

17-Year Coronary Angiographic Series of Sirolimus-Eluting Stent-Induced Giant Aneurysms: Stent-Assisted Coil Embolization.

Korean circulation journal·2026
Same journal

Illuminating the Role of RNA Epigenetics in Abdominal Aortic Aneurysm: The Impact of YTHDF3 on Vascular Smooth Muscle Cell Fate.

Korean circulation journal·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K

The Emerging Lipid Risk: Lipoprotein(a).

Sang-Hak Lee1, Ki Hoon Han2

  • 1Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. shl1106@yuhs.ac.

Korean Circulation Journal
|December 10, 2025
PubMed
Summary
This summary is machine-generated.

Lipoprotein(a) (Lp(a)) is a key genetic risk factor for cardiovascular disease and aortic stenosis. New therapies targeting Lp(a) show promise in lowering levels, but clinical outcomes are pending.

Keywords:
Coronary artery diseaseLipidsPharmacologyPreventive medicine

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Related Experiment Videos

Last Updated: Jan 9, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.3K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Area of Science:

  • Cardiology
  • Genetics
  • Biochemistry

Background:

  • Lipoprotein(a) (Lp(a)) is a recognized causal risk factor for atherosclerotic cardiovascular disease and aortic stenosis.
  • Elevated Lp(a) levels (≥50 mg/dL) indicate increased cardiovascular risk, influenced by genetic factors like the kringle IV type 2 repeat variant.
  • Lp(a) shares structural similarities with LDL but includes apolipoprotein(a) (apo(a)), contributing to its atherogenic and thrombogenic properties.

Purpose of the Study:

  • To review the role of Lp(a) as a cardiovascular risk factor.
  • To discuss the mechanisms by which Lp(a) promotes atherosclerosis and valve calcification.
  • To summarize ongoing therapeutic strategies targeting Lp(a).

Main Methods:

  • Epidemiological and genetic studies.
  • Analysis of Lp(a) structure and function.
  • Review of ongoing clinical trials for Lp(a)-lowering therapies.

Main Results:

  • Lp(a) promotes atherosclerosis via LDL-like properties and apo(a) interactions with vascular cells.
  • Apo(a) interferes with fibrinolysis and oxidized phospholipids on apo(a) enhance oxidative stress and valve calcification.
  • Investigational therapies (antisense oligonucleotides, siRNAs, small molecules) have demonstrated significant Lp(a) level reductions (80-100%) in trials.

Conclusions:

  • Lp(a) is a significant, genetically determined risk factor for cardiovascular and valvular diseases.
  • Emerging therapies show potent Lp(a) lowering capabilities.
  • Further clinical outcome data are needed to confirm the efficacy of these novel Lp(a)-targeting treatments.